- Home
- POR vs GH Comparison
POR vs GH Comparison
Compare POR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POR
- GH
- Stock Information
- Founded
- POR 1889
- GH 2011
- Country
- POR United States
- GH United States
- Employees
- POR N/A
- GH N/A
- Industry
- POR Electric Utilities: Central
- GH Medical Specialities
- Sector
- POR Utilities
- GH Health Care
- Exchange
- POR Nasdaq
- GH Nasdaq
- Market Cap
- POR 4.7B
- GH 4.9B
- IPO Year
- POR N/A
- GH 2018
- Fundamental
- Price
- POR $44.61
- GH $65.46
- Analyst Decision
- POR Hold
- GH Strong Buy
- Analyst Count
- POR 11
- GH 22
- Target Price
- POR $46.30
- GH $64.91
- AVG Volume (30 Days)
- POR 1.1M
- GH 2.2M
- Earning Date
- POR 10-31-2025
- GH 10-29-2025
- Dividend Yield
- POR 4.71%
- GH N/A
- EPS Growth
- POR N/A
- GH N/A
- EPS
- POR 2.72
- GH N/A
- Revenue
- POR $3,488,000,000.00
- GH $828,849,000.00
- Revenue This Year
- POR $4.88
- GH $28.30
- Revenue Next Year
- POR $4.79
- GH $22.98
- P/E Ratio
- POR $16.38
- GH N/A
- Revenue Growth
- POR 8.53
- GH 28.74
- 52 Week Low
- POR $39.55
- GH $20.14
- 52 Week High
- POR $49.85
- GH $68.23
- Technical
- Relative Strength Index (RSI)
- POR 63.29
- GH 59.00
- Support Level
- POR $43.15
- GH $61.00
- Resistance Level
- POR $44.21
- GH $68.22
- Average True Range (ATR)
- POR 0.58
- GH 2.50
- MACD
- POR 0.04
- GH 0.12
- Stochastic Oscillator
- POR 94.20
- GH 64.47
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 100 megawatts of energy storage.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.